nodes	percent_of_prediction	percent_of_DWPC	metapath
Montelukast—ALOX5—Balsalazide—Crohn's disease	0.319	0.361	CbGbCtD
Montelukast—ALOX5—Mesalazine—Crohn's disease	0.255	0.289	CbGbCtD
Montelukast—ALOX5—Sulfasalazine—Crohn's disease	0.143	0.161	CbGbCtD
Montelukast—PTGS1—Balsalazide—Crohn's disease	0.0718	0.0811	CbGbCtD
Montelukast—PTGS1—Mesalazine—Crohn's disease	0.0574	0.0649	CbGbCtD
Montelukast—PTGS1—Sulfasalazine—Crohn's disease	0.0321	0.0362	CbGbCtD
Montelukast—Varicella—Azathioprine—Crohn's disease	0.0064	0.0779	CcSEcCtD
Montelukast—CYP3A4—Prednisone—Crohn's disease	0.006	0.00678	CbGbCtD
Montelukast—ALOX5—Synthesis of 5-eicosatetraenoic acids—GPX4—Crohn's disease	0.00461	0.151	CbGpPWpGaD
Montelukast—Pulmonary eosinophilia—Mesalazine—Crohn's disease	0.00432	0.0526	CcSEcCtD
Montelukast—CYSLTR1—Eicosanoid ligand-binding receptors—PTGER4—Crohn's disease	0.00203	0.0668	CbGpPWpGaD
Montelukast—Hepatitis cholestatic—Mesalazine—Crohn's disease	0.00196	0.0238	CcSEcCtD
Montelukast—Erythema nodosum—Mesalazine—Crohn's disease	0.00182	0.0222	CcSEcCtD
Montelukast—Liver injury—Mercaptopurine—Crohn's disease	0.00173	0.021	CcSEcCtD
Montelukast—Hepatocellular injury—Mercaptopurine—Crohn's disease	0.00145	0.0177	CcSEcCtD
Montelukast—Foetor hepaticus—Mesalazine—Crohn's disease	0.00139	0.0169	CcSEcCtD
Montelukast—Liver disorder—Mesalazine—Crohn's disease	0.00116	0.0141	CcSEcCtD
Montelukast—Dermatitis atopic—Mesalazine—Crohn's disease	0.00107	0.013	CcSEcCtD
Montelukast—Liver injury—Azathioprine—Crohn's disease	0.00103	0.0125	CcSEcCtD
Montelukast—Rhinorrhoea—Mesalazine—Crohn's disease	0.000974	0.0119	CcSEcCtD
Montelukast—Liver injury—Mesalazine—Crohn's disease	0.000938	0.0114	CcSEcCtD
Montelukast—Pancreatitis—Mercaptopurine—Crohn's disease	0.000894	0.0109	CcSEcCtD
Montelukast—Vasculitis—Azathioprine—Crohn's disease	0.000888	0.0108	CcSEcCtD
Montelukast—Trauma—Prednisone—Crohn's disease	0.000877	0.0107	CcSEcCtD
Montelukast—Bone disorder—Mesalazine—Crohn's disease	0.000874	0.0106	CcSEcCtD
Montelukast—Hepatocellular injury—Azathioprine—Crohn's disease	0.000866	0.0105	CcSEcCtD
Montelukast—ALOX5—Arachidonic acid metabolism—GPX4—Crohn's disease	0.000845	0.0277	CbGpPWpGaD
Montelukast—SLCO2B1—Transport of organic anions—ALB—Crohn's disease	0.00081	0.0266	CbGpPWpGaD
Montelukast—Hepatocellular injury—Mesalazine—Crohn's disease	0.000789	0.0096	CcSEcCtD
Montelukast—Hepatobiliary disease—Mercaptopurine—Crohn's disease	0.000769	0.00936	CcSEcCtD
Montelukast—Neuropathy—Mesalazine—Crohn's disease	0.000741	0.00902	CcSEcCtD
Montelukast—Ear pain—Mesalazine—Crohn's disease	0.000671	0.00817	CcSEcCtD
Montelukast—CYSLTR1—G alpha (q) signalling events—MLN—Crohn's disease	0.000669	0.022	CbGpPWpGaD
Montelukast—Immune system disorder—Mercaptopurine—Crohn's disease	0.000659	0.00803	CcSEcCtD
Montelukast—Gastroenteritis—Mesalazine—Crohn's disease	0.000646	0.00786	CcSEcCtD
Montelukast—Disorientation—Mesalazine—Crohn's disease	0.00064	0.00779	CcSEcCtD
Montelukast—Eczema—Mesalazine—Crohn's disease	0.000637	0.00776	CcSEcCtD
Montelukast—Thirst—Mesalazine—Crohn's disease	0.000602	0.00732	CcSEcCtD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MLN—Crohn's disease	0.000598	0.0196	CbGpPWpGaD
Montelukast—Toxic epidermal necrolysis—Azathioprine—Crohn's disease	0.000566	0.00689	CcSEcCtD
Montelukast—Dermatitis atopic—Prednisone—Crohn's disease	0.000564	0.00686	CcSEcCtD
Montelukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—ACKR2—Crohn's disease	0.000545	0.0179	CbGpPWpGaD
Montelukast—Arthralgia—Mercaptopurine—Crohn's disease	0.000541	0.00659	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.000537	0.00654	CcSEcCtD
Montelukast—ALOX5—Selenium Micronutrient Network—GPX4—Crohn's disease	0.000537	0.0176	CbGpPWpGaD
Montelukast—Pancreatitis—Azathioprine—Crohn's disease	0.000533	0.00648	CcSEcCtD
Montelukast—Memory impairment—Prednisone—Crohn's disease	0.000532	0.00647	CcSEcCtD
Montelukast—Oedema—Mercaptopurine—Crohn's disease	0.000519	0.00631	CcSEcCtD
Montelukast—Aspartate aminotransferase increased—Mesalazine—Crohn's disease	0.000516	0.00628	CcSEcCtD
Montelukast—Cramp muscle—Mesalazine—Crohn's disease	0.000516	0.00628	CcSEcCtD
Montelukast—Nasopharyngitis—Mesalazine—Crohn's disease	0.000512	0.00623	CcSEcCtD
Montelukast—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.000508	0.00618	CcSEcCtD
Montelukast—Alanine aminotransferase increased—Mesalazine—Crohn's disease	0.000505	0.00615	CcSEcCtD
Montelukast—Skin disorder—Mercaptopurine—Crohn's disease	0.000504	0.00613	CcSEcCtD
Montelukast—Asthma—Mesalazine—Crohn's disease	0.000495	0.00602	CcSEcCtD
Montelukast—Influenza—Mesalazine—Crohn's disease	0.000495	0.00602	CcSEcCtD
Montelukast—Eosinophilia—Mesalazine—Crohn's disease	0.00049	0.00597	CcSEcCtD
Montelukast—Pneumonia—Azathioprine—Crohn's disease	0.000487	0.00593	CcSEcCtD
Montelukast—Pancreatitis—Mesalazine—Crohn's disease	0.000485	0.00591	CcSEcCtD
Montelukast—Infestation—Azathioprine—Crohn's disease	0.000485	0.0059	CcSEcCtD
Montelukast—Infestation NOS—Azathioprine—Crohn's disease	0.000485	0.0059	CcSEcCtD
Montelukast—Stevens-Johnson syndrome—Azathioprine—Crohn's disease	0.00048	0.00585	CcSEcCtD
Montelukast—Contusion—Prednisone—Crohn's disease	0.000479	0.00582	CcSEcCtD
Montelukast—Bronchitis—Mesalazine—Crohn's disease	0.000476	0.00579	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.000473	0.00575	CcSEcCtD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—ACKR2—Crohn's disease	0.000467	0.0153	CbGpPWpGaD
Montelukast—Viral infection—Prednisone—Crohn's disease	0.000462	0.00563	CcSEcCtD
Montelukast—Upper respiratory tract infection—Mesalazine—Crohn's disease	0.00046	0.0056	CcSEcCtD
Montelukast—Hepatobiliary disease—Azathioprine—Crohn's disease	0.000458	0.00558	CcSEcCtD
Montelukast—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.000448	0.00545	CcSEcCtD
Montelukast—Pneumonia—Mesalazine—Crohn's disease	0.000444	0.0054	CcSEcCtD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—MLN—Crohn's disease	0.000443	0.0145	CbGpPWpGaD
Montelukast—Infestation—Mesalazine—Crohn's disease	0.000441	0.00537	CcSEcCtD
Montelukast—Infestation NOS—Mesalazine—Crohn's disease	0.000441	0.00537	CcSEcCtD
Montelukast—Stevens-Johnson syndrome—Mesalazine—Crohn's disease	0.000438	0.00533	CcSEcCtD
Montelukast—Neuropathy peripheral—Mesalazine—Crohn's disease	0.000433	0.00527	CcSEcCtD
Montelukast—CYSLTR1—G alpha (q) signalling events—GPR65—Crohn's disease	0.000431	0.0141	CbGpPWpGaD
Montelukast—Jaundice—Mesalazine—Crohn's disease	0.00043	0.00524	CcSEcCtD
Montelukast—Conjunctivitis—Mesalazine—Crohn's disease	0.000429	0.00522	CcSEcCtD
Montelukast—Vasculitis—Prednisone—Crohn's disease	0.000428	0.00521	CcSEcCtD
Montelukast—Hepatobiliary disease—Mesalazine—Crohn's disease	0.000417	0.00508	CcSEcCtD
Montelukast—Epistaxis—Mesalazine—Crohn's disease	0.000416	0.00507	CcSEcCtD
Montelukast—Sinusitis—Mesalazine—Crohn's disease	0.000414	0.00504	CcSEcCtD
Montelukast—Erythema multiforme—Azathioprine—Crohn's disease	0.000411	0.00501	CcSEcCtD
Montelukast—Body temperature increased—Mercaptopurine—Crohn's disease	0.00041	0.00499	CcSEcCtD
Montelukast—ALOX5—Selenium Micronutrient Network—MPO—Crohn's disease	0.00041	0.0135	CbGpPWpGaD
Montelukast—ALOX5—Eicosanoid Synthesis—PTGS2—Crohn's disease	0.000409	0.0134	CbGpPWpGaD
Montelukast—Rhinitis—Mesalazine—Crohn's disease	0.000397	0.00483	CcSEcCtD
Montelukast—Hepatitis—Mesalazine—Crohn's disease	0.000396	0.00482	CcSEcCtD
Montelukast—Pharyngitis—Mesalazine—Crohn's disease	0.000393	0.00479	CcSEcCtD
Montelukast—Immune system disorder—Azathioprine—Crohn's disease	0.000393	0.00478	CcSEcCtD
Montelukast—PTGS1—Prostaglandin Synthesis and Regulation—PTGER4—Crohn's disease	0.000393	0.0129	CbGpPWpGaD
Montelukast—Mediastinal disorder—Azathioprine—Crohn's disease	0.000392	0.00477	CcSEcCtD
Montelukast—Neuropathy—Prednisone—Crohn's disease	0.000392	0.00477	CcSEcCtD
Montelukast—Urinary tract disorder—Mesalazine—Crohn's disease	0.000391	0.00476	CcSEcCtD
Montelukast—Connective tissue disorder—Mesalazine—Crohn's disease	0.000389	0.00474	CcSEcCtD
Montelukast—Urethral disorder—Mesalazine—Crohn's disease	0.000388	0.00473	CcSEcCtD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GPR65—Crohn's disease	0.000385	0.0127	CbGpPWpGaD
Montelukast—Hypersensitivity—Mercaptopurine—Crohn's disease	0.000382	0.00465	CcSEcCtD
Montelukast—Erythema multiforme—Mesalazine—Crohn's disease	0.000375	0.00456	CcSEcCtD
Montelukast—Cardiac disorder—Mesalazine—Crohn's disease	0.000368	0.00448	CcSEcCtD
Montelukast—PTGS1—Arachidonic acid metabolism—GPX4—Crohn's disease	0.000366	0.012	CbGpPWpGaD
Montelukast—Hyperkinesia—Prednisone—Crohn's disease	0.000364	0.00443	CcSEcCtD
Montelukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—CCR9—Crohn's disease	0.000358	0.0118	CbGpPWpGaD
Montelukast—Immune system disorder—Mesalazine—Crohn's disease	0.000358	0.00436	CcSEcCtD
Montelukast—Mediastinal disorder—Mesalazine—Crohn's disease	0.000357	0.00435	CcSEcCtD
Montelukast—CYSLTR1—GPCR ligand binding—ACKR2—Crohn's disease	0.000356	0.0117	CbGpPWpGaD
Montelukast—Diarrhoea—Mercaptopurine—Crohn's disease	0.000355	0.00432	CcSEcCtD
Montelukast—Mental disorder—Mesalazine—Crohn's disease	0.000347	0.00422	CcSEcCtD
Montelukast—CYSLTR1—GPCR ligand binding—MLN—Crohn's disease	0.000337	0.0111	CbGpPWpGaD
Montelukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—GPR65—Crohn's disease	0.000333	0.0109	CbGpPWpGaD
Montelukast—Muscle spasms—Mesalazine—Crohn's disease	0.000332	0.00404	CcSEcCtD
Montelukast—CYSLTR1—smooth muscle tissue—Crohn's disease	0.000331	0.139	CbGeAlD
Montelukast—Vomiting—Mercaptopurine—Crohn's disease	0.00033	0.00401	CcSEcCtD
Montelukast—Injury—Prednisone—Crohn's disease	0.00033	0.00401	CcSEcCtD
Montelukast—Rash—Mercaptopurine—Crohn's disease	0.000327	0.00398	CcSEcCtD
Montelukast—Dermatitis—Mercaptopurine—Crohn's disease	0.000327	0.00398	CcSEcCtD
Montelukast—Tremor—Mesalazine—Crohn's disease	0.000323	0.00393	CcSEcCtD
Montelukast—Myalgia—Azathioprine—Crohn's disease	0.000322	0.00392	CcSEcCtD
Montelukast—Arthralgia—Azathioprine—Crohn's disease	0.000322	0.00392	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.00032	0.0039	CcSEcCtD
Montelukast—PTGS1—Overview of nanoparticle effects—CRP—Crohn's disease	0.000319	0.0105	CbGpPWpGaD
Montelukast—Angioedema—Mesalazine—Crohn's disease	0.000315	0.00384	CcSEcCtD
Montelukast—Nausea—Mercaptopurine—Crohn's disease	0.000308	0.00375	CcSEcCtD
Montelukast—Infection—Azathioprine—Crohn's disease	0.000307	0.00374	CcSEcCtD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	0.000307	0.0101	CbGpPWpGaD
Montelukast—Palpitations—Mesalazine—Crohn's disease	0.000305	0.00371	CcSEcCtD
Montelukast—Thrombocytopenia—Azathioprine—Crohn's disease	0.000303	0.00368	CcSEcCtD
Montelukast—Cough—Mesalazine—Crohn's disease	0.000301	0.00366	CcSEcCtD
Montelukast—SLCO2B1—Transport of vitamins, nucleosides, and related molecules—ALB—Crohn's disease	0.0003	0.00986	CbGpPWpGaD
Montelukast—Skin disorder—Azathioprine—Crohn's disease	0.0003	0.00365	CcSEcCtD
Montelukast—CYSLTR1—mammalian vulva—Crohn's disease	0.000298	0.125	CbGeAlD
Montelukast—Myalgia—Mesalazine—Crohn's disease	0.000294	0.00357	CcSEcCtD
Montelukast—Arthralgia—Mesalazine—Crohn's disease	0.000294	0.00357	CcSEcCtD
Montelukast—Anxiety—Mesalazine—Crohn's disease	0.000293	0.00356	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.000292	0.00355	CcSEcCtD
Montelukast—Irritability—Prednisone—Crohn's disease	0.000289	0.00352	CcSEcCtD
Montelukast—SLCO2B1—SLC-mediated transmembrane transport—SLC22A5—Crohn's disease	0.000288	0.00944	CbGpPWpGaD
Montelukast—SLCO2B1—SLC-mediated transmembrane transport—SLC22A4—Crohn's disease	0.000288	0.00944	CbGpPWpGaD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.000285	0.00937	CbGpPWpGaD
Montelukast—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.000282	0.00343	CcSEcCtD
Montelukast—Oedema—Mesalazine—Crohn's disease	0.000282	0.00343	CcSEcCtD
Montelukast—Anaphylactic shock—Mesalazine—Crohn's disease	0.000282	0.00343	CcSEcCtD
Montelukast—Infection—Mesalazine—Crohn's disease	0.00028	0.0034	CcSEcCtD
Montelukast—Nervous system disorder—Mesalazine—Crohn's disease	0.000276	0.00336	CcSEcCtD
Montelukast—Thrombocytopenia—Mesalazine—Crohn's disease	0.000276	0.00335	CcSEcCtD
Montelukast—Skin disorder—Mesalazine—Crohn's disease	0.000273	0.00333	CcSEcCtD
Montelukast—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—Crohn's disease	0.000273	0.00895	CbGpPWpGaD
Montelukast—Alanine aminotransferase increased—Prednisone—Crohn's disease	0.000267	0.00325	CcSEcCtD
Montelukast—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.000267	0.00325	CcSEcCtD
Montelukast—CYSLTR1—lymphoid tissue—Crohn's disease	0.000264	0.111	CbGeAlD
Montelukast—CYSLTR1—Endothelins—JAK2—Crohn's disease	0.000259	0.0085	CbGpPWpGaD
Montelukast—Pancreatitis—Prednisone—Crohn's disease	0.000257	0.00313	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.000256	0.00312	CcSEcCtD
Montelukast—Insomnia—Mesalazine—Crohn's disease	0.000255	0.0031	CcSEcCtD
Montelukast—Paraesthesia—Mesalazine—Crohn's disease	0.000253	0.00308	CcSEcCtD
Montelukast—Gastrointestinal pain—Azathioprine—Crohn's disease	0.000253	0.00308	CcSEcCtD
Montelukast—Somnolence—Mesalazine—Crohn's disease	0.00025	0.00305	CcSEcCtD
Montelukast—Dyspepsia—Mesalazine—Crohn's disease	0.000248	0.00302	CcSEcCtD
Montelukast—Body temperature increased—Azathioprine—Crohn's disease	0.000244	0.00297	CcSEcCtD
Montelukast—Abdominal pain—Azathioprine—Crohn's disease	0.000244	0.00297	CcSEcCtD
Montelukast—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.000243	0.00296	CcSEcCtD
Montelukast—Fatigue—Mesalazine—Crohn's disease	0.000243	0.00295	CcSEcCtD
Montelukast—Pain—Mesalazine—Crohn's disease	0.000241	0.00293	CcSEcCtD
Montelukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—CCR6—Crohn's disease	0.000237	0.00779	CbGpPWpGaD
Montelukast—CYP2C8—Arachidonic acid metabolism—GPX4—Crohn's disease	0.000237	0.00777	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR ligand binding—CCR9—Crohn's disease	0.000234	0.00767	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—GPX4—Crohn's disease	0.000233	0.00765	CbGpPWpGaD
Montelukast—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—Crohn's disease	0.000232	0.00761	CbGpPWpGaD
Montelukast—Gastrointestinal pain—Mesalazine—Crohn's disease	0.00023	0.0028	CcSEcCtD
Montelukast—Neuropathy peripheral—Prednisone—Crohn's disease	0.000229	0.00279	CcSEcCtD
Montelukast—Hypersensitivity—Azathioprine—Crohn's disease	0.000228	0.00277	CcSEcCtD
Montelukast—ALOX5—Arachidonic acid metabolism—PTGS2—Crohn's disease	0.000227	0.00746	CbGpPWpGaD
Montelukast—Urticaria—Mesalazine—Crohn's disease	0.000224	0.00272	CcSEcCtD
Montelukast—CYSLTR1—G alpha (q) signalling events—RASGRP1—Crohn's disease	0.000223	0.00731	CbGpPWpGaD
Montelukast—Abdominal pain—Mesalazine—Crohn's disease	0.000223	0.00271	CcSEcCtD
Montelukast—Body temperature increased—Mesalazine—Crohn's disease	0.000223	0.00271	CcSEcCtD
Montelukast—CYSLTR1—GPCR ligand binding—GPR65—Crohn's disease	0.000217	0.00713	CbGpPWpGaD
Montelukast—ALOX5—Selenium Micronutrient Network—CRP—Crohn's disease	0.000216	0.00708	CbGpPWpGaD
Montelukast—PTGS1—Overview of nanoparticle effects—PTGS2—Crohn's disease	0.000214	0.00701	CbGpPWpGaD
Montelukast—Diarrhoea—Azathioprine—Crohn's disease	0.000211	0.00257	CcSEcCtD
Montelukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—PTGER4—Crohn's disease	0.000209	0.00686	CbGpPWpGaD
Montelukast—Hallucination—Prednisone—Crohn's disease	0.000209	0.00254	CcSEcCtD
Montelukast—Hypersensitivity—Mesalazine—Crohn's disease	0.000207	0.00252	CcSEcCtD
Montelukast—PTGS1—Overview of nanoparticle effects—CXCL8—Crohn's disease	0.000207	0.0068	CbGpPWpGaD
Montelukast—Connective tissue disorder—Prednisone—Crohn's disease	0.000206	0.00251	CcSEcCtD
Montelukast—Dizziness—Azathioprine—Crohn's disease	0.000204	0.00249	CcSEcCtD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.000203	0.00668	CbGpPWpGaD
Montelukast—SLCO2B1—SLC-mediated transmembrane transport—GCKR—Crohn's disease	0.000203	0.00665	CbGpPWpGaD
Montelukast—Asthenia—Mesalazine—Crohn's disease	0.000202	0.00246	CcSEcCtD
Montelukast—ALOX5—smooth muscle tissue—Crohn's disease	0.0002	0.0841	CbGeAlD
Montelukast—Pruritus—Mesalazine—Crohn's disease	0.000199	0.00242	CcSEcCtD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—Crohn's disease	0.000199	0.00654	CbGpPWpGaD
Montelukast—ALOX5—Selenium Micronutrient Network—ICAM1—Crohn's disease	0.000198	0.0065	CbGpPWpGaD
Montelukast—Vomiting—Azathioprine—Crohn's disease	0.000197	0.00239	CcSEcCtD
Montelukast—Rash—Azathioprine—Crohn's disease	0.000195	0.00237	CcSEcCtD
Montelukast—Dermatitis—Azathioprine—Crohn's disease	0.000195	0.00237	CcSEcCtD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.000195	0.00639	CbGpPWpGaD
Montelukast—Headache—Azathioprine—Crohn's disease	0.000194	0.00236	CcSEcCtD
Montelukast—Diarrhoea—Mesalazine—Crohn's disease	0.000193	0.00234	CcSEcCtD
Montelukast—CYP2C9—Arachidonic acid metabolism—GPX4—Crohn's disease	0.000193	0.00632	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—MLN—Crohn's disease	0.000191	0.00626	CbGpPWpGaD
Montelukast—Immune system disorder—Prednisone—Crohn's disease	0.000189	0.0023	CcSEcCtD
Montelukast—Dizziness—Mesalazine—Crohn's disease	0.000186	0.00227	CcSEcCtD
Montelukast—Mental disorder—Prednisone—Crohn's disease	0.000184	0.00224	CcSEcCtD
Montelukast—Nausea—Azathioprine—Crohn's disease	0.000184	0.00223	CcSEcCtD
Montelukast—CYSLTR1—Signaling by GPCR—ACKR2—Crohn's disease	0.000183	0.00599	CbGpPWpGaD
Montelukast—SLCO2B1—SLC-mediated transmembrane transport—SLC11A1—Crohn's disease	0.000179	0.00588	CbGpPWpGaD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.000179	0.00588	CbGpPWpGaD
Montelukast—Vomiting—Mesalazine—Crohn's disease	0.000179	0.00218	CcSEcCtD
Montelukast—PTGS1—Selenium Micronutrient Network—MPO—Crohn's disease	0.000178	0.00583	CbGpPWpGaD
Montelukast—Rash—Mesalazine—Crohn's disease	0.000178	0.00216	CcSEcCtD
Montelukast—Dermatitis—Mesalazine—Crohn's disease	0.000177	0.00216	CcSEcCtD
Montelukast—PTGS1—Eicosanoid Synthesis—PTGS2—Crohn's disease	0.000177	0.00582	CbGpPWpGaD
Montelukast—Headache—Mesalazine—Crohn's disease	0.000176	0.00215	CcSEcCtD
Montelukast—CYSLTR1—Signaling by GPCR—MLN—Crohn's disease	0.000173	0.00568	CbGpPWpGaD
Montelukast—Agitation—Prednisone—Crohn's disease	0.000168	0.00204	CcSEcCtD
Montelukast—Nausea—Mesalazine—Crohn's disease	0.000167	0.00204	CcSEcCtD
Montelukast—Angioedema—Prednisone—Crohn's disease	0.000167	0.00203	CcSEcCtD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	0.000165	0.00543	CbGpPWpGaD
Montelukast—ALOX5—Selenium Micronutrient Network—ALB—Crohn's disease	0.000165	0.00542	CbGpPWpGaD
Montelukast—ALOX5—lymphoid tissue—Crohn's disease	0.00016	0.0672	CbGeAlD
Montelukast—Convulsion—Prednisone—Crohn's disease	0.000158	0.00192	CcSEcCtD
Montelukast—ALOX5—digestive system—Crohn's disease	0.000158	0.0664	CbGeAlD
Montelukast—Arthralgia—Prednisone—Crohn's disease	0.000155	0.00189	CcSEcCtD
Montelukast—Myalgia—Prednisone—Crohn's disease	0.000155	0.00189	CcSEcCtD
Montelukast—Anxiety—Prednisone—Crohn's disease	0.000155	0.00188	CcSEcCtD
Montelukast—CYSLTR1—GPCR ligand binding—CCR6—Crohn's disease	0.000155	0.00508	CbGpPWpGaD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.000154	0.00188	CcSEcCtD
Montelukast—ALOX5—Selenium Micronutrient Network—IFNG—Crohn's disease	0.000151	0.00495	CbGpPWpGaD
Montelukast—CYSLTR1—lymph node—Crohn's disease	0.000149	0.0627	CbGeAlD
Montelukast—Oedema—Prednisone—Crohn's disease	0.000149	0.00181	CcSEcCtD
Montelukast—Anaphylactic shock—Prednisone—Crohn's disease	0.000149	0.00181	CcSEcCtD
Montelukast—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—Crohn's disease	0.000148	0.00487	CbGpPWpGaD
Montelukast—Infection—Prednisone—Crohn's disease	0.000148	0.0018	CcSEcCtD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	0.000146	0.0048	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	0.000146	0.0048	CbGpPWpGaD
Montelukast—Nervous system disorder—Prednisone—Crohn's disease	0.000146	0.00178	CcSEcCtD
Montelukast—Skin disorder—Prednisone—Crohn's disease	0.000145	0.00176	CcSEcCtD
Montelukast—ALOX5—Selenium Micronutrient Network—PTGS2—Crohn's disease	0.000145	0.00474	CbGpPWpGaD
Montelukast—PTGS1—Overview of nanoparticle effects—TNF—Crohn's disease	0.000144	0.00473	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR ligand binding—PTGER4—Crohn's disease	0.000136	0.00448	CbGpPWpGaD
Montelukast—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000136	0.00165	CcSEcCtD
Montelukast—Insomnia—Prednisone—Crohn's disease	0.000135	0.00164	CcSEcCtD
Montelukast—ALOX5—Selenium Micronutrient Network—IL1B—Crohn's disease	0.000134	0.00441	CbGpPWpGaD
Montelukast—Paraesthesia—Prednisone—Crohn's disease	0.000134	0.00163	CcSEcCtD
Montelukast—CYSLTR1—GPCR downstream signaling—CCR9—Crohn's disease	0.000132	0.00434	CbGpPWpGaD
Montelukast—Dyspepsia—Prednisone—Crohn's disease	0.000131	0.0016	CcSEcCtD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	0.000129	0.00423	CbGpPWpGaD
Montelukast—Fatigue—Prednisone—Crohn's disease	0.000128	0.00156	CcSEcCtD
Montelukast—CYSLTR1—GPCR downstream signaling—GPR65—Crohn's disease	0.000123	0.00403	CbGpPWpGaD
Montelukast—Gastrointestinal pain—Prednisone—Crohn's disease	0.000122	0.00148	CcSEcCtD
Montelukast—SLCO2B1—digestive system—Crohn's disease	0.000122	0.0511	CbGeAlD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	0.000121	0.00396	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—CCR9—Crohn's disease	0.00012	0.00394	CbGpPWpGaD
Montelukast—Urticaria—Prednisone—Crohn's disease	0.000118	0.00144	CcSEcCtD
Montelukast—Abdominal pain—Prednisone—Crohn's disease	0.000118	0.00143	CcSEcCtD
Montelukast—Body temperature increased—Prednisone—Crohn's disease	0.000118	0.00143	CcSEcCtD
Montelukast—PTGS1—Overview of nanoparticle effects—IL6—Crohn's disease	0.000116	0.00382	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—GPR65—Crohn's disease	0.000112	0.00366	CbGpPWpGaD
Montelukast—Hypersensitivity—Prednisone—Crohn's disease	0.00011	0.00134	CcSEcCtD
Montelukast—CYSLTR1—Signaling Pathways—ACKR2—Crohn's disease	0.000108	0.00354	CbGpPWpGaD
Montelukast—Asthenia—Prednisone—Crohn's disease	0.000107	0.0013	CcSEcCtD
Montelukast—Pruritus—Prednisone—Crohn's disease	0.000105	0.00128	CcSEcCtD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—GCKR—Crohn's disease	0.000103	0.00338	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—MLN—Crohn's disease	0.000102	0.00336	CbGpPWpGaD
Montelukast—Diarrhoea—Prednisone—Crohn's disease	0.000102	0.00124	CcSEcCtD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—Crohn's disease	0.000102	0.00334	CbGpPWpGaD
Montelukast—Dizziness—Prednisone—Crohn's disease	9.85e-05	0.0012	CcSEcCtD
Montelukast—PTGS1—Arachidonic acid metabolism—PTGS2—Crohn's disease	9.85e-05	0.00323	CbGpPWpGaD
Montelukast—ALOX5—Selenium Micronutrient Network—TNF—Crohn's disease	9.76e-05	0.0032	CbGpPWpGaD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—Crohn's disease	9.7e-05	0.00318	CbGpPWpGaD
Montelukast—Vomiting—Prednisone—Crohn's disease	9.47e-05	0.00115	CcSEcCtD
Montelukast—Rash—Prednisone—Crohn's disease	9.39e-05	0.00114	CcSEcCtD
Montelukast—Dermatitis—Prednisone—Crohn's disease	9.38e-05	0.00114	CcSEcCtD
Montelukast—CYSLTR1—Signaling Pathways—TAGAP—Crohn's disease	9.35e-05	0.00307	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—CRP—Crohn's disease	9.34e-05	0.00307	CbGpPWpGaD
Montelukast—Headache—Prednisone—Crohn's disease	9.33e-05	0.00114	CcSEcCtD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	9.1e-05	0.00299	CbGpPWpGaD
Montelukast—ALOX5—lymph node—Crohn's disease	9.03e-05	0.0379	CbGeAlD
Montelukast—Nausea—Prednisone—Crohn's disease	8.85e-05	0.00108	CcSEcCtD
Montelukast—CYSLTR1—GPCR downstream signaling—CCR6—Crohn's disease	8.75e-05	0.00287	CbGpPWpGaD
Montelukast—CYP2C8—Metapathway biotransformation—GPX4—Crohn's disease	8.68e-05	0.00285	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—PLA2G4F—Crohn's disease	8.67e-05	0.00285	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—ICAM1—Crohn's disease	8.59e-05	0.00282	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	8.44e-05	0.00277	CbGpPWpGaD
Montelukast—PTGS1—epithelium—Crohn's disease	8.34e-05	0.035	CbGeAlD
Montelukast—CYSLTR1—Signaling Pathways—RSPO3—Crohn's disease	8.17e-05	0.00268	CbGpPWpGaD
Montelukast—PTGS1—smooth muscle tissue—Crohn's disease	8.04e-05	0.0338	CbGeAlD
Montelukast—CYSLTR1—Signaling by GPCR—CCR6—Crohn's disease	7.95e-05	0.00261	CbGpPWpGaD
Montelukast—PTGS1—skin of body—Crohn's disease	7.93e-05	0.0333	CbGeAlD
Montelukast—ALOX5—Selenium Micronutrient Network—IL6—Crohn's disease	7.87e-05	0.00258	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—SEL1L—Crohn's disease	7.75e-05	0.00254	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—PTGER4—Crohn's disease	7.7e-05	0.00253	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—MTMR3—Crohn's disease	7.37e-05	0.00242	CbGpPWpGaD
Montelukast—PTGS1—mammalian vulva—Crohn's disease	7.24e-05	0.0304	CbGeAlD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	7.18e-05	0.00236	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—ALB—Crohn's disease	7.16e-05	0.00235	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CCR9—Crohn's disease	7.09e-05	0.00233	CbGpPWpGaD
Montelukast—CYP2C9—Metapathway biotransformation—GPX4—Crohn's disease	7.07e-05	0.00232	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—PTGER4—Crohn's disease	7e-05	0.0023	CbGpPWpGaD
Montelukast—SLCO2B1—lymph node—Crohn's disease	6.95e-05	0.0292	CbGeAlD
Montelukast—CYP2C9—digestive system—Crohn's disease	6.95e-05	0.0292	CbGeAlD
Montelukast—CYSLTR1—Signaling Pathways—GPR65—Crohn's disease	6.59e-05	0.00216	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—IL3—Crohn's disease	6.56e-05	0.00215	CbGpPWpGaD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	6.55e-05	0.00215	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—IFNG—Crohn's disease	6.54e-05	0.00215	CbGpPWpGaD
Montelukast—SLCO2B1—SLC-mediated transmembrane transport—ALB—Crohn's disease	6.45e-05	0.00212	CbGpPWpGaD
Montelukast—CYP2C8—Arachidonic acid metabolism—PTGS2—Crohn's disease	6.36e-05	0.00209	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—RASGRP1—Crohn's disease	6.35e-05	0.00208	CbGpPWpGaD
Montelukast—PTGS1—digestive system—Crohn's disease	6.35e-05	0.0267	CbGeAlD
Montelukast—PTGS1—Selenium Micronutrient Network—PTGS2—Crohn's disease	6.27e-05	0.00206	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—IL3—Crohn's disease	5.96e-05	0.00196	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—IL1B—Crohn's disease	5.83e-05	0.00191	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—RASGRP1—Crohn's disease	5.76e-05	0.00189	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—FADS1—Crohn's disease	5.74e-05	0.00188	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	5.59e-05	0.00184	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	5.45e-05	0.00179	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—GPX4—Crohn's disease	5.38e-05	0.00177	CbGpPWpGaD
Montelukast—CYP3A4—digestive system—Crohn's disease	5.3e-05	0.0223	CbGeAlD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	5.23e-05	0.00172	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—GCKR—Crohn's disease	5.19e-05	0.0017	CbGpPWpGaD
Montelukast—CYP2C9—Arachidonic acid metabolism—PTGS2—Crohn's disease	5.18e-05	0.0017	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR ligand binding—CXCL8—Crohn's disease	4.99e-05	0.00164	CbGpPWpGaD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	4.97e-05	0.00163	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CCR6—Crohn's disease	4.69e-05	0.00154	CbGpPWpGaD
Montelukast—CYP3A4—Metapathway biotransformation—GPX4—Crohn's disease	4.66e-05	0.00153	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	4.63e-05	0.00152	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—IL2RA—Crohn's disease	4.6e-05	0.00151	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	4.44e-05	0.00146	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—RBX1—Crohn's disease	4.25e-05	0.00139	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—TNF—Crohn's disease	4.23e-05	0.00139	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—IL2RA—Crohn's disease	4.17e-05	0.00137	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—PTGER4—Crohn's disease	4.13e-05	0.00136	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	3.77e-05	0.00124	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—PLA2G4F—Crohn's disease	3.76e-05	0.00123	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—UBE2D1—Crohn's disease	3.72e-05	0.00122	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	3.71e-05	0.00122	CbGpPWpGaD
Montelukast—PTGS1—lymph node—Crohn's disease	3.62e-05	0.0152	CbGeAlD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	3.61e-05	0.00119	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—RIPK2—Crohn's disease	3.61e-05	0.00119	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—PLA2G4F—Crohn's disease	3.55e-05	0.00117	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—IL3—Crohn's disease	3.52e-05	0.00116	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—IL6—Crohn's disease	3.41e-05	0.00112	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—RASGRP1—Crohn's disease	3.4e-05	0.00112	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	3.38e-05	0.00111	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—ALB—Crohn's disease	3.28e-05	0.00108	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	3.25e-05	0.00107	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—MTMR3—Crohn's disease	3.2e-05	0.00105	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—JAK2—Crohn's disease	3.09e-05	0.00101	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—SOCS1—Crohn's disease	3.08e-05	0.00101	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—MTMR3—Crohn's disease	3.02e-05	0.000992	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—TYK2—Crohn's disease	2.94e-05	0.000966	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	2.94e-05	0.000965	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—CXCL8—Crohn's disease	2.82e-05	0.000926	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—JAK2—Crohn's disease	2.81e-05	0.000921	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	2.75e-05	0.000903	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—SMAD3—Crohn's disease	2.66e-05	0.000874	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—CXCL8—Crohn's disease	2.56e-05	0.000841	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—FADS1—Crohn's disease	2.49e-05	0.000817	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—IL2RA—Crohn's disease	2.47e-05	0.00081	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—PLA2G4F—Crohn's disease	2.43e-05	0.000797	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—FADS1—Crohn's disease	2.35e-05	0.000773	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—GPX4—Crohn's disease	2.33e-05	0.000765	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—GCKR—Crohn's disease	2.25e-05	0.000739	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—GPX4—Crohn's disease	2.2e-05	0.000724	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—GCKR—Crohn's disease	2.13e-05	0.000699	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—MTMR3—Crohn's disease	2.06e-05	0.000678	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—PLA2G4F—Crohn's disease	1.98e-05	0.000649	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—TYK2—Crohn's disease	1.74e-05	0.00057	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—MTMR3—Crohn's disease	1.68e-05	0.000552	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—JAK2—Crohn's disease	1.66e-05	0.000544	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—ALB—Crohn's disease	1.65e-05	0.000543	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.61e-05	0.000528	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—FADS1—Crohn's disease	1.61e-05	0.000528	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CXCL8—Crohn's disease	1.51e-05	0.000497	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—GPX4—Crohn's disease	1.51e-05	0.000494	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—GCKR—Crohn's disease	1.45e-05	0.000477	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—PTGS2—Crohn's disease	1.45e-05	0.000475	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—IL6—Crohn's disease	1.44e-05	0.000472	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.41e-05	0.000462	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—FADS1—Crohn's disease	1.31e-05	0.00043	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—PLA2G4F—Crohn's disease	1.3e-05	0.000428	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—GPX4—Crohn's disease	1.23e-05	0.000402	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—STAT3—Crohn's disease	1.22e-05	0.000399	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—GCKR—Crohn's disease	1.18e-05	0.000389	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—MTMR3—Crohn's disease	1.11e-05	0.000364	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.04e-05	0.000341	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	9.09e-06	0.000299	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—FADS1—Crohn's disease	8.63e-06	0.000283	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—IL6—Crohn's disease	8.5e-06	0.000279	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	8.46e-06	0.000278	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—GPX4—Crohn's disease	8.08e-06	0.000265	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—GCKR—Crohn's disease	7.81e-06	0.000256	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	7.4e-06	0.000243	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—ALB—Crohn's disease	7.17e-06	0.000235	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—ALB—Crohn's disease	6.78e-06	0.000222	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—PTGS2—Crohn's disease	6.27e-06	0.000206	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—PTGS2—Crohn's disease	5.93e-06	0.000195	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—ALB—Crohn's disease	4.63e-06	0.000152	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—PTGS2—Crohn's disease	4.05e-06	0.000133	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—ALB—Crohn's disease	3.77e-06	0.000124	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—PTGS2—Crohn's disease	3.3e-06	0.000108	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—ALB—Crohn's disease	2.48e-06	8.16e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—PTGS2—Crohn's disease	2.17e-06	7.14e-05	CbGpPWpGaD
